PEGylated VRB plus quinacrine cationic liposomes for treating non-small cell lung cancer

References

• Vasekar M, Liu X, Zheng H, Belani CP. Targeted immunotherapy for non-small cell lung cancer. World J Clin Oncol 2014;5:39–47
   PubMedGoogle Scholar
• Dearing KR, Sangal A, Weiss GJ. Maintaining clarity: review of maintenance therapy in non-small cell lung cancer. World J Clin Oncol 2014;5:103–13
   PubMedGoogle Scholar
• Cheng I, Huang FZ, Cheng IF, et al. GE11-modified liposomes for non-small cell lung cancer targeting: preparation, ex vitro and in vivo evaluation. Int J Nanomed 2014;9:921–35
   PubMed Web of Science ®Google Scholar
• Andresen TL, Jensen SS, Jorgensen K. Advanced strategies in liposomal cancer therapy: problems and prospects of active and tumor specific drug release. Prog Lipid Res 2005;44:68–97
   PubMed Web of Science ®Google Scholar
• Campbell RB, Fukumura D, Brown EB, et al. Cationic charge determines the distribution of liposomes between the vascular and extravascular compartments of tumors. Cancer Res 2002;62:6831–6
   PubMed Web of Science ®Google Scholar
• Biswas S, Deshpande PP, Perche F, et al. Octa-arginine-modified pegylated liposomal doxorubicin: an effective treatment strategy for non-small cell lung cancer. Cancer Lett 2013;335:191–200
   PubMed Web of Science ®Google Scholar
• Chandaroy P, Sen A, Alexandridis P, Hui SW. Utilizing temperature-sensitive association of Pluronic F-127 with lipid bilayers to control liposome-cell adhesion. Biochim Biophys Acta 2002;1559:32–42
   PubMed Web of Science ®Google Scholar
• Ishida K, Hirose T, Yokouchi J, et al. Phase II study of concurrent chemoradiotherapy with carboplatin and vinorelbine for locally advanced non-small-cell lung cancer. Mol Clin Oncol 2014;2:405–10
   PubMedGoogle Scholar
• Mutlu H, Buyukcelik A. The combination of weekly trastuzumab plus vinorelbine may be preferable regimen in HER-2 positive breast cancer patients with brain metastasis. J Oncol Pharm Pract 2014;4:143–7
   Google Scholar
• Blasinska-Morawiec M, Tubiana-Mathieu N, Fougeray R, et al. Phase II study of intravenous vinflunine after failure of first-line vinorelbine based regimen for advanced breast cancer. Breast 2013;22:58–63
   PubMed Web of Science ®Google Scholar
• Barret A, Tagliavini F, Forloni G, et al. Evaluation of quinacrine treatment for prion diseases. J Virol 2003;77:8462–9
   PubMed Web of Science ®Google Scholar
• Fasanmade AA, Owuor ED, Ee RP, et al. Quinacrine induces cytochrome c-dependent apoptotic signaling in human cervical carcinoma cells. Arch Pharm Res 2001;24:126–35
   PubMed Web of Science ®Google Scholar
• Wang XX, Li YB, Yao HJ, et al. The use of mitochondrial targeting resveratrol liposomes modified with a dequalinium polyethylene glycol-distearoylphosphatidyl ethanolamine conjugate to induce apoptosis in resistant lung cancer cells. Biomaterials 2011;32:5673–87
   PubMed Web of Science ®Google Scholar
• Ma X, Zhou J, Zhang CX, et al. Modulation of drug-resistant membrane and apoptosis proteins of breast cancer stem cells by targeting berberine liposomes. Biomaterials 2013;34:4452–65
   PubMed Web of Science ®Google Scholar
• Lv Q, Li IM, Han M, et al. Characteristics of sequential targeting of brain glioma for transferrin-modified cisplatin liposome. Int J Pharm 2013;444:1–9
   PubMed Web of Science ®Google Scholar
• Du J, Lu WI, Ying X, et al. Dual-targeting topotecan liposomes modified with tamoxifen and wheat germ agglutinin significantly improve drug transport across the blood–brain barrier and survival of brain tumor-bearing animals. Mol Pharm 2009;6:905–17
   PubMed Web of Science ®Google Scholar
• Li l, Geisler I, Chmielewski J, Cheng JX. Cationic amphiphilic polyproline helix P11LRR targets intracellular mitochondria. J Control Release 2010;142:259–66
   PubMed Web of Science ®Google Scholar
• Abbott NJ, Ronnback l, Hansson E. Astrocyte-endothelial interactions at the blood–brain barrier. Nat Rev Neurosci 2006;7:41–53
   PubMed Web of Science ®Google Scholar
• Ju RJ, Li XT, Shi JF, et al. Liposomes, modified with PTD peptide, containing epirubicin and celecoxib, to target vasculogenic mimicry channels in invasive breast cancer. Biomaterials 2014;26:7610–21
   Web of Science ®Google Scholar
• Li XY, Zhao Y, Sun MG, et al. Multifunctional liposomes loaded with paclitaxel and artemether for treatment of invasive brain glioma. Biomaterials 2014;35:5591–604
   PubMed Web of Science ®Google Scholar
• Zheng N, Dai WB, Du WW, et al. A novel lanreotide-encoded Micelle system targets paclitaxel to the tumors with overexpression of somatostatin receptors. Mol Pharm 2012;9:1175–88
   PubMed Web of Science ®Google Scholar
• Park K. Questions on the role of the EPR effect in tumor targeting. J Control Release 2013;172:391
   PubMed Web of Science ®Google Scholar
• Meyer O, Kirpotin D, Hong K, et al. Cationic liposomes coated with polyethylene glycol as carriers for oligonucleotides. J Biol Chem 1998;273:15621–7
   PubMed Web of Science ®Google Scholar
• Jung SH, Jung SH, Seong H, et al. Polyethylene glycol-complexed cationic liposome for enhanced cellular uptake and anticancer activity. Int J Pharm 2009;382:254–61
   PubMed Web of Science ®Google Scholar
• Zhang I, Yao HJ, Yu Y, et al. Mitochondrial targeting liposomes incorporating daunorubicin and quinacrine for treatment of relapsed breast cancer arising from cancer stem cells. Biomaterials 2012;33:565–82
   PubMed Web of Science ®Google Scholar
• Kirschmann DA, Seftor EA, Hardy KM, et al. Molecular pathways: vasculogenic mimicry in tumor cells: diagnostic and therapeutic implications. Clin Cancer Res 2012;18:2726–32
   PubMed Web of Science ®Google Scholar
• Kelly PN, Strasser A. The role of Bcl-2 and its pro-survival relatives in tumourigenesis and cancer therapy. Cell Death Differ 2011;18:1414–24
   PubMed Web of Science ®Google Scholar
• Berge EO, Huun J, Lillehaug JR, et al. Functional characterisation of p53 mutants identified in breast cancers with suboptimal responses to anthracyclines or mitomycin. Biochim Biophys Acta 2013;1830:2790–7
   PubMed Web of Science ®Google Scholar
• Ying X, Wen H, Lu WI, et al. Dual-targeting daunorubicin liposomes improve the therapeutic efficacy of brain glioma in animals. J Control Release 2010;141:183–92
   PubMed Web of Science ®Google Scholar